**HL7 Patient Care Work Group**

 **Allergy/Intolerance/Adverse Reaction Topic Sub-Group Meeting Minutes**

**Date: August 19, 2015**

Phone Number: +1 770-657-9270
 Participant Passcode: 943377

WEBEX: [www.webex.com](http://www.webex.com)

ID: 197 520 889

Co-Chairs: Stephen Chu/Elaine Ayres Scribe: Elaine Ayres

|  |  |
| --- | --- |
| **Name** | **Present on August 19, 2015** |
| Elaine Ayres |  |
| Stephen Chu | X |
| Rob Hausam |  |
| Russ Leftwich |  |
| Emma Jones | X |
| Lisa Nelson | X |

**Agenda for August 19, 2015**

1. **Review agenda**
2. **Approve minutes from August 5, 2015**
3. **Agenda items for Atlanta WG.**
4. **Update from SDWG on DSTU comments**
5. **Value sets for allergies (substances)**
6. **Look at C-CDA risk template (Lisa) , and FHIR resources for risk (CDS), and clinical impression**
7. **Agenda for September 2**

August 5 minutes Move to approve: Abstain - , Negatives - , Approve - (did not have a quorum)

**Atlanta WG meeting – discuss topics with Russ.**

Propose we use Wednesday Q4 as a discussion of the substance terminology.

Implementation guide for C-CDA is a key project.

Continue to work on FHIR/Open EHR

Look at future direction of DSTU

**Discussion of Risk Template in C-CDA**

Note that the Health Concerns section Includes both Health Concern Act and Risk Concern Act clinical statements. The outer most layer of any nested statements should be the should have the status/state model associated with it. Currently the health concern and risk concern overlaps with the model of problem concern.

The C-CDA risk model lacks the granularity that is necessary to address the concept of an adverse reaction risk.

The group discussed the current C-CDA R2.1 – and why the template for Substance or Device Allergy or Intolerance Observation does not have criticality.

Substance or Device Allergy - Intolerance Observation (V2) [observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.24.3.90:2014-06-09 (open)]

Table 488: Substance or Device Allergy - Intolerance Observation (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Health Concern Act (V2)](#E_Health_Concern_Act_V2) (optional)[Risk Concern Act (V2)](#E_Risk_Concern_Act_V2) (optional) | [Allergy Status Observation (DEPRECATED)](#E_Allergy_Status_Observation_DEPRECATED)[Author Participation](#U_Author_Participation)[Reaction Observation (V2)](#Reaction_Observation_V2)[Severity Observation (V2)](#E_Severity_Observation_V2) |

 It appears to be associated with a reaction and the severity of the reaction, but it is not clear why both templates are necessary. Is this template necessary in order to display the substance that caused the reaction? Will seek clarification on this.

Discussed the use of various terminologies included in the table associated with the Allergy Intolerance template above – will renew efforts to find a path forward not just for C-CDA but for other HL7 standards. We briefly discussed the ability to use structured product labels and GS1 coding as a universal alternative.

**Agenda for September 2, 2015**

1. **Review agenda**
2. **Approve minutes from August 5 and August 19, 2015**
3. **Agenda items for Atlanta WG.**
4. **Update from SDWG on DSTU comments**
5. **Value sets for allergies (substances)**
6. **Look at C-CDA risk template (Lisa) , and FHIR resources for risk (CDS), and clinical impression**
7. **Agenda for September 16**